AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3932106 — intervention group
Group type: COMPARATOR
Intervention: Terfenadine 60 mg b.i.d.
Number of subjects: 174
Study 31386926 — intervention group
Group type: EXPERIMENTAL
Intervention: Labin electronic dynamometer
Number of subjects: 34
Study 31386926 — intervention group
Group type: COMPARATOR
Intervention: Jamar hydraulic hand dynamometer
Number of subjects: 34
Study 29317111 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium Respimat® 5 and 2.5μg
Number of subjects: 17116
Study 25965388 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week spiritual reminiscence intervention
Number of subjects: 103
Study 25965388 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 103
Study 25139882 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucagon 25 μg
Number of subjects: 11
Study 25139882 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucagon 75 μg
Number of subjects: 11
Study 25139882 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucagon 125 μg
Number of subjects: 11
Study 25139882 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucagon 175 μg
Number of subjects: 11
Study 25139882 — intervention group
Group type: COMPARATOR
Intervention: High insulin levels (0.05 units/kg/h)
Number of subjects: 11
Study 22935145 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived severity of nonmelanoma skin cancer
Number of subjects: 999
Study 22935145 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived severity of melanoma
Number of subjects: 999
Study 22935145 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived susceptibility to skin cancer
Number of subjects: 999
Study 22935145 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI-for-age
Number of subjects: 999
Study 20706110 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent CPT (thrice weekly)
Number of subjects: 324
Study 20706110 — intervention group
Group type: COMPARATOR
Intervention: Daily CPT
Number of subjects: 324
Study 19102975 — intervention group
Group type: EXPERIMENTAL
Intervention: TMMU formula for fluid resuscitation
Number of subjects: 71
Study 16798862 — intervention group
Group type: EXPERIMENTAL
Intervention: Atraumatic Restorative Treatment (ART) with high-viscosity glass ionomer
Number of subjects: 681
Study 16798862 — intervention group
Group type: COMPARATOR
Intervention: Traditional approach (TA) with amalgam
Number of subjects: 681
Study 14714836 — intervention group
Group type: EXPERIMENTAL
Intervention: Aesthetic Plus
Number of subjects: 225
Study 14714836 — intervention group
Group type: EXPERIMENTAL
Intervention: DT
Number of subjects: 225
Study 14714836 — intervention group
Group type: EXPERIMENTAL
Intervention: FRC Postec
Number of subjects: 225
Study 10974963 — intervention group
Group type: EXPERIMENTAL
Intervention: Active medication review by a pharmacist
Number of subjects: 330
Study 8788406 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency contracting with a partner
Number of subjects: 84
Study 8788406 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency contracting alone
Number of subjects: 84
Study 8788406 — intervention group
Group type: COMPARATOR
Intervention: No contingency contracting
Number of subjects: 84
Study 1323576 — intervention group
Group type: EXPERIMENTAL
Intervention: 10(6) TCID50 of CP18 PIV‐3 vaccine administered intranasally to seropositive older children (41 to 124 months)
Number of subjects: 95
Study 1323576 — intervention group
Group type: EXPERIMENTAL
Intervention: 10(5) TCID50 of CP18 PIV‐3 vaccine administered intranasally to seropositive young children
Number of subjects: 95
Study 1323576 — intervention group
Group type: EXPERIMENTAL
Intervention: 10(6) TCID50 of CP18 PIV‐3 vaccine administered intranasally to seropositive young children
Number of subjects: 95
Study 1323576 — intervention group
Group type: EXPERIMENTAL
Intervention: 10(6) TCID50 of CP18 PIV‐3 vaccine administered intranasally to seronegative young children
Number of subjects: 95
Study 1323576 — intervention group
Group type: EXPERIMENTAL
Intervention: CP18 PIV‐3 vaccine in seronegative young children
Number of subjects: 95
Study 1323576 — intervention group
Group type: COMPARATOR
Intervention: Vaccine virus spread from a vaccinated child to a sibling control
Number of subjects: 95
Study 6829580 — intervention group
Group type: EXPERIMENTAL
Intervention: ROA format
Number of subjects: 271
Study 6829580 — intervention group
Group type: EXPERIMENTAL
Intervention: R format
Number of subjects: 271
Study 6829580 — intervention group
Group type: COMPARATOR
Intervention: Control group (no written information)
Number of subjects: 271
Study 31168922 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (5-6 weekly aerobic and combined aerobic and strength training sessions, 30-60 minutes, individual dietary plans aiming for BMI ≤25 kg/m2)
Number of subjects: 98
Study 31168922 — intervention group
Group type: COMPARATOR
Intervention: Standard care (standardized, blinded, target-driven medical therapy during the initial 12 months)
Number of subjects: 98
Study 31168922 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (considering lost to follow-up as relapsed)
Number of subjects: 98
Study 30170399 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese medicine fumigation 'Bone-healing Powder'
Number of subjects: 0
Study 30170399 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 0
Study 27210235 — intervention group
Group type: EXPERIMENTAL
Intervention: BoNT/A injection (100 units)
Number of subjects: 46
Study 27210235 — intervention group
Group type: COMPARATOR
Intervention: Control group (education only)
Number of subjects: 46
Study 25219601 — intervention group
Group type: EXPERIMENTAL
Intervention: Baicalein (100-2800 mg)
Number of subjects: 72
Study 22727067 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of nateglinide (60 mg)
Number of subjects: 20
Study 22727067 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation of nateglinide (60 mg)
Number of subjects: 20
Study 19655157 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethinylestradiol + cyproterone acetate (2 mg, EE/CA)
Number of subjects: 56
Study 19655157 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethinylestradiol + cyproterone acetate (2 mg, EE/CA) with spironolactone (Sp)
Number of subjects: 56
Study 17585086 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (1200 mg/d for 10 days, tapered thereafter)
Number of subjects: 71
Study 17585086 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 16040590 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic exercise program (12-week duration)
Number of subjects: 100
Study 12110042 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-lipoic acid (test)
Number of subjects: 60
Study 12110042 — intervention group
Group type: COMPARATOR
Intervention: Cellulose starch (placebo)
Number of subjects: 60
Study 10549990 — intervention group
Group type: EXPERIMENTAL
Intervention: GHB (50 mg/kg body weight for 10 days)
Number of subjects: 60
Study 10549990 — intervention group
Group type: COMPARATOR
Intervention: Diazepam (0.5-0.75 mg/kg body weight for 6 days, tapering the dose 25% daily until day 10)
Number of subjects: 60
Study 7634674 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment for avulsion fractures (no immobilization)
Number of subjects: 100
Study 7634674 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment for shaft/neck fractures (plaster casts with weight bearing as tolerated)
Number of subjects: 100
Study 7634674 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment for true Jones' fractures (8 weeks nonweight bearing followed by weight bearing as tolerated in a cast)
Number of subjects: 100
Study 7634674 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical fixation for conservative treatment failure
Number of subjects: 100
Study 2179764 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 X 10(6) IU IFN subcutaneously daily for 6 months
Number of subjects: 50
Study 2179764 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 6781372 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized allergen provocations
Number of subjects: 18
Study 6781372 — intervention group
Group type: COMPARATOR
Intervention: Negative provocations
Number of subjects: 18
Study 6781372 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretreatment with disodium cromoglycate and ICI 74.917
Number of subjects: 18
Study 31989758 — intervention group
Group type: EXPERIMENTAL
Intervention: Standards for Co‐production of Education (Mental Health Nursing) (SCo‐PE [MHN])
Number of subjects: 50
Study 30972062 — intervention group
Group type: EXPERIMENTAL
Intervention: Myeloid-derived cells targeted treatments
Number of subjects: 0
Study 30972062 — intervention group
Group type: EXPERIMENTAL
Intervention: Preclinical studies and clinical trials
Number of subjects: 0
Study 27677368 — intervention group
Group type: EXPERIMENTAL
Intervention: Corn oil (CO)
Number of subjects: 54
Study 27677368 — intervention group
Group type: COMPARATOR
Intervention: Extra-virgin olive oil (EVOO)
Number of subjects: 54
Study 26445823 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous fibrin glue
Number of subjects: 171
Study 26445823 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercial porcine fibrin sealants
Number of subjects: 171
Study 26445823 — intervention group
Group type: COMPARATOR
Intervention: Drainage cessation
Number of subjects: 171
Study 23356823 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus acidophilus (4 × 10^9 colony‐forming units/day) for 5 days
Number of subjects: 300
Study 23356823 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study 21261786 — intervention group
Group type: COMPARATOR
Intervention: Zinc
Number of subjects: 480
Study 21261786 — intervention group
Group type: COMPARATOR
Intervention: S. boulardii plus zinc
Number of subjects: 480
Study 21261786 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc plus S. boulardii
Number of subjects: 480
Study 21261786 — intervention group
Group type: EXPERIMENTAL
Intervention: S. boulardii plus lactose-free formula
Number of subjects: 480
Study 21261786 — intervention group
Group type: COMPARATOR
Intervention: Lactose-free formula
Number of subjects: 480
Study 21261786 — intervention group
Group type: COMPARATOR
Intervention: S. boulardii
Number of subjects: 480
Study 21261786 — intervention group
Group type: COMPARATOR
Intervention: Oral and/or parenteral rehydration solutions
Number of subjects: 480
Study 19479626 — intervention group
Group type: EXPERIMENTAL
Intervention: Quercetin (250 mg)
Number of subjects: 63
Study 19479626 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 19479626 — intervention group
Group type: EXPERIMENTAL
Intervention: Quercetin
Number of subjects: 63
Study 19479626 — intervention group
Group type: EXPERIMENTAL
Intervention: Quercetin and Placebo
Number of subjects: 63
Study 17901387 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinzaparin
Number of subjects: 1484
Study 17901387 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 1484
Study 15319599 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc nanocolloid (99mTc‐NC) (10 MBq) and 111In‐HIG (2 MBq) as a mixture (0.2 ml)
Number of subjects: 10
Study 15319599 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc‐HIG (10 MBq) and 111In‐HIG (2 MBq) as a mixture (0.2 ml)
Number of subjects: 10
Study 15319599 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc‐HIG (10 MBq) and 111In‐HIG (2 MBq) separately (both 0.2 ml)
Number of subjects: 10
Study 11552184 — intervention group
Group type: EXPERIMENTAL
Intervention: Tizanidine
Number of subjects: 17
Study 9611088 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan depletion (TD) challenge with 43 g of an amino acid mixture containing five large neutral amino acids
Number of subjects: 20
Study 9611088 — intervention group
Group type: COMPARATOR
Intervention: Control group received the same amino acid mixture with 2.3 g tryptophan added
Number of subjects: 20
Study 9611088 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline cortisol levels in responders to TD
Number of subjects: 20
Study 9611088 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of platelet serotonin-receptor function and plasma prolactin levels
Number of subjects: 20
Study 9611088 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline data correlation between rated mood state and plasma cortisol
Number of subjects: 20
Study 9611088 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline data correlation between rated mood state and plasma tryptophan concentration
Number of subjects: 20
Study 7803993 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralipid 20% (long‐chain triglycerides)
Number of subjects: 23
Study 7803993 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipofundin MCT/LCT 20% (10% each of long‐ and medium‐chain triglycerides)
Number of subjects: 23
Study 3052916 — intervention group
Group type: EXPERIMENTAL
Intervention: Right Heart Cooling (RHC)
Number of subjects: 78
Study 3052916 — intervention group
Group type: COMPARATOR
Intervention: Standard Protection (SC)
Number of subjects: 78
Study 30999382 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined massage therapy and phototherapy
Number of subjects: 83
Study 30999382 — intervention group
Group type: COMPARATOR
Intervention: Phototherapy (Control)
Number of subjects: 83
Study 28343774 — intervention group
Group type: EXPERIMENTAL
Intervention: 60μg recombinant hepatitis B vaccine
Number of subjects: 196
Study 28343774 — intervention group
Group type: COMPARATOR
Intervention: 20μg recombinant hepatitis B vaccine
Number of subjects: 196
Study 28343774 — intervention group
Group type: EXPERIMENTAL
Intervention: Both 20μg and 60μg vaccine groups
Number of subjects: 196
Study 26521577 — intervention group
Group type: EXPERIMENTAL
Intervention: Matrix needling technique combined with rehabilitation training
Number of subjects: 60
Study 26521577 — intervention group
Group type: COMPARATOR
Intervention: Conventional rehabilitation therapy (intermittent catheterization and bladder function training)
Number of subjects: 60
Study 23578949 — intervention group
Group type: COMPARATOR
Intervention: Standard Intrauterine Insemination (SIUI)
Number of subjects: 417
Study 23578949 — intervention group
Group type: EXPERIMENTAL
Intervention: Fallopian Tube Sperm Perfusion (FSP)
Number of subjects: 417
Study 22083887 — intervention group
Group type: EXPERIMENTAL
Intervention: BWA‐LCAP (Bodyweight adjusted leukocytapheresis)
Number of subjects: 28
Study 22083887 — intervention group
Group type: COMPARATOR
Intervention: Routine 3,000 mL LCAP
Number of subjects: 28
Study 19111212 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-row technique (group 1)
Number of subjects: 80
Study 19111212 — intervention group
Group type: COMPARATOR
Intervention: Double-row technique (group 2)
Number of subjects: 80
Study 16723422 — intervention group
Group type: EXPERIMENTAL
Intervention: Habit reversal (HR)
Number of subjects: 25
Study 16723422 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 25
Study 15073160 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG) at a dosage of 300-500 mg/kg (most commonly 400 mg/kg)
Number of subjects: 5
Study 15073160 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG)
Number of subjects: 5
Study 11319684 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV-11 L1 VLP vaccine
Number of subjects: 0
Study 9141913 — intervention group
Group type: EXPERIMENTAL
Intervention: ACEI-treated patients
Number of subjects: 18
Study 9141913 — intervention group
Group type: COMPARATOR
Intervention: Control group (not treated with ACEIs)
Number of subjects: 18
Study 8431574 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-poor plasma (PPP), n = 12
Number of subjects: 36
Study 8431574 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP), n = 12
Number of subjects: 36
Study 8431574 — intervention group
Group type: COMPARATOR
Intervention: Control group (no APP), n = 12
Number of subjects: 36
Study 2446080 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ketanserin (0.15 mg/kg)
Number of subjects: 10
Study 29861437 — intervention group
Group type: EXPERIMENTAL
Intervention: PM2.5 level averaged over 14 days
Number of subjects: 16
Study 29861437 — intervention group
Group type: EXPERIMENTAL
Intervention: PM2.5 level averaged over 10 days
Number of subjects: 16
Study 27466602 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy-dairy protein blend (PB) supplementation (22 g daily)
Number of subjects: 68
Study 27466602 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein (WP) isolate supplementation
Number of subjects: 68
Study 27466602 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric maltodextrin (MDP) placebo
Number of subjects: 68
Study 27466602 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined PB and WP treatments
Number of subjects: 68
Study 27466602 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments (PB, WP, MDP)
Number of subjects: 68
Study 25017822 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS assessments+feedback (SA+F)
Number of subjects: 765
Study 25017822 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 765
Study 25017822 — intervention group
Group type: COMPARATOR
Intervention: SMS assessments (SA)
Number of subjects: 765
Study 22690981 — intervention group
Group type: EXPERIMENTAL
Intervention: Postdischarge care transition (PDCT) program
Number of subjects: 333
Study 22690981 — intervention group
Group type: COMPARATOR
Intervention: Regular discharge process (control)
Number of subjects: 333
Study 20202095 — intervention group
Group type: EXPERIMENTAL
Intervention: Acrylic-based resilient liner (ARL)
Number of subjects: 74
Study 20202095 — intervention group
Group type: COMPARATOR
Intervention: Conventional acrylic resin (CAR)
Number of subjects: 74
Study 18547727 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram 20mg once daily
Number of subjects: 41
Study 18547727 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 15647413 — intervention group
Group type: EXPERIMENTAL
Intervention: Hibiscus sabdariffa L. extract (150 mL yielding 62.6 mg of cyanidin‐3‐sambubioside, 81.6 mg of delphinidin‐3‐sambubioside, and 147.4 mg of total anthocyanins)
Number of subjects: 6
Study 15647413 — intervention group
Group type: EXPERIMENTAL
Intervention: Hibiscus sabdariffa L. extract
Number of subjects: 6
Study 12003051 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Error of Measurement (SEM)
Number of subjects: 198
Study 12003051 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma Quality of Life Questionnaire (AQLQ)
Number of subjects: 198
Study 10862852 — intervention group
Group type: EXPERIMENTAL
Intervention: Laminaria
Number of subjects: 321
Study 10862852 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E(2) gel (0.5 microg every 6 hours for two doses followed by oxytocin if indicated)
Number of subjects: 321
Study 10862852 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra-amniotic saline infusion
Number of subjects: 321
Study 10862852 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 321
Study 9089422 — intervention group
Group type: EXPERIMENTAL
Intervention: AZT-P-ddI (IVX-E-59) intravenous administration (50 mg and 100 mg)
Number of subjects: 12
Study 9089422 — intervention group
Group type: EXPERIMENTAL
Intervention: AZT-P-ddI (IVX-E-59) oral administration (100 mg and 200 mg)
Number of subjects: 12
Study 9089422 — intervention group
Group type: EXPERIMENTAL
Intervention: 450 mg oral dose of AZT-P-ddI
Number of subjects: 12
Study 9089422 — intervention group
Group type: EXPERIMENTAL
Intervention: AZT-P-ddI (IVX-E-59) oral administration
Number of subjects: 12
Study 9089422 — intervention group
Group type: EXPERIMENTAL
Intervention: AZT-P-ddI (IVX-E-59) oral and intravenous administration
Number of subjects: 12
Study 8478959 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 g/m2 DFMO every day (step 3)
Number of subjects: 32
Study 8478959 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.125, 0.25, 0.5, or 0.75 g/m2 DFMO four times a day (step 1)
Number of subjects: 32
Study 8478959 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.125 or 0.25 g/m2 four times a day or 0.5 or 1.0 g/m2 every day (step 2)
Number of subjects: 32
Study 8478959 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 g/m2 DFMO every day
Number of subjects: 32
Study 3090945 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed yellow tunable dye laser (577-nm wavelength)
Number of subjects: 3
Study 3090945 — intervention group
Group type: COMPARATOR
Intervention: Argon laser
Number of subjects: 3
Study 3090945 — intervention group
Group type: COMPARATOR
Intervention: Carbon dioxide laser
Number of subjects: 3
Study 3090945 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed yellow dye laser
Number of subjects: 3
Study 29739994 — intervention group
Group type: EXPERIMENTAL
Intervention: Body Mass Index (BMI)
Number of subjects: 322154
Study 29739994 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip Circumference (HC)
Number of subjects: 322154
Study 29739994 — intervention group
Group type: EXPERIMENTAL
Intervention: Waist Circumference (WC)
Number of subjects: 322154
Study 29739994 — intervention group
Group type: EXPERIMENTAL
Intervention: Waist-Hip Ratio (WHR)
Number of subjects: 322154
Study 29739994 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI-adjusted HC and WC
Number of subjects: 322154
Study 29739994 — intervention group
Group type: EXPERIMENTAL
Intervention: Central adiposity (WHR)
Number of subjects: 322154
Study 27128958 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline (50 mg twice per day)
Number of subjects: 46
Study 27128958 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 24452704 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A injection at the proximal 2/10 and 3/10 of calf length
Number of subjects: 40
Study 24452704 — intervention group
Group type: COMPARATOR
Intervention: Botulinum toxin A injection at and below the midbelly of the muscle (Control)
Number of subjects: 40
Study 22157067 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI-guided treatment decision (group 2)
Number of subjects: 0
Study 22157067 — intervention group
Group type: COMPARATOR
Intervention: MRI-blinded treatment decision (group 1)
Number of subjects: 0
Study 22157067 — intervention group
Group type: COMPARATOR
Intervention: Different injection than proposed by independent physician (group 1)
Number of subjects: 0
Study 22157067 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection correlated with imaging (group 1)
Number of subjects: 0